While the expression of markers related to antigen-presentation, such as CD80 and CD86 (66), as well as ligands for immune checkpoints, such as PD-L1, remained unchanged, there was a significant downregulation of CD206 expression in macrophages taken from tumors resulted from ATP6AP2KD cancer cells (Figures 5D–I). The gene discussed is CD86; the disease is cancer.